Drug Profile
Research programme: oncology vaccines - Theravectys
Alternative Names: THV 02Latest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator THERAVECTYS
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- No development reported Adult T-cell leukaemia-lymphoma
Most Recent Events
- 21 Mar 2023 The development of research programme is ongoing for cancer
- 28 Feb 2019 No recent reports of development identified for preclinical development in Adult T cell leukaemia-lymphoma in France (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)